首頁 › 腎臟癌（腎細胞癌） › 德克薩斯州 › Houston
Houston, TX 的 腎臟癌（腎細胞癌） 臨床試驗
35 項針對 腎臟癌（腎細胞癌） 的研究正在 Houston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
招募中1 期
- NEO-811 Houston Site, Houston
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- UT MD Anderson Cancer Center, Houston
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
招募中1/2 期
- University of Texas - MD Anderson Cancer Center, Houston
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
招募中2 期
- UT MD Anderson Cancer Center, Houston
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
招募中2 期
- M D Anderson Cancer Center, Houston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
招募中1/2 期
- Texas Oncology - Gulf Coast, Houston
- University of Texas MD Anderson Cancer Center, Houston
- Texas Oncology - Gulf Coast, Houston
- 還有 1 項
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
招募中1/2 期
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
招募中1 期
- Md Anderson Cancer Center, Houston
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
招募中3 期
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Houston Methodist Hospital, Houston
- Methodist Willowbrook Hospital, Houston
- 還有 1 項
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
招募中2 期
- MD Anderson Cancer Center, Houston
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
招募中2 期
- The University of Texas M. D. Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
招募中1/2 期
- Research Site, Houston
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
招募中1/2 期
- Houston Methodist Hospital, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study
招募中1 期
- The University of Texas M. D. Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
PET/MR for Characterization of Renal Masses (RMs)
招募中觀察性研究
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
招募中1/2 期
- MD Anderson Cancer Center, Houston
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
招募中1 期
- UT MD Anderson, Houston
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
招募中1 期
- M D Anderson Cancer Center, Houston
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
招募中1/2 期
- MD Anderson Cancer Center, Houston
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
招募中1 期
- MD Anderson Cancer Center, Houston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center /ID# 252004, Houston
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
招募中2 期
- MD Anderson Cancer Center, Houston
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
招募中2 期
- M D Anderson Cancer Center, Houston
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
招募中1/2 期
- MD Anderson Cancer Center, Houston
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
招募中
- M D Anderson Cancer Center, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
招募中1/2 期
- MD Anderson Cancer Center, Houston
A Study of VET3-TGI in Patients With Solid Tumors
招募中1 期
- University of Texas MD Anderson Cancer Center, Houston
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
招募中1 期
- The University of Texas MD Anderson Cancer Center, Houston
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
招募中3 期
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of IBI363 in Subjects with Advanced Solid Malignancies
招募中2 期
- MD Anderson Cancer Center-University of Texas, Houston
- Oncology Consultants P.A., Houston
其他城市的 腎臟癌（腎細胞癌） 試驗
- New York City, NY27 項研究
- Dallas, TX23 項研究
- Nashville, TN23 項研究
- St. Louis, MO23 項研究
- Los Angeles, CA20 項研究
- Boston, MA16 項研究
- Baldwin Park, CA16 項研究
- Pittsburgh, PA15 項研究
- Philadelphia, PA15 項研究
- Queens, NY15 項研究
- Cleveland, OH14 項研究
- Rochester, MN14 項研究
Houston 的其他研究
- 非小細胞肺癌145 項研究
- 乳癌126 項研究
- 癌症（所有類型）121 項研究
- 轉移性癌症104 項研究
- 大腸直腸癌102 項研究
- 卵巢癌89 項研究
- 急性髓系白血病85 項研究
- 肺癌78 項研究
- 前列腺癌76 項研究
- 子宮內膜癌68 項研究
- 胰臟癌61 項研究
- 黑色素瘤59 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。